Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Memorial Sloan Kettering Cancer Center · Cornell University · +30 more institutions
Indexed incrossrefpubmed
Abstract
Background
fusion-positive solid tumors are unclear.
Methods
fusion-positive cancer involving any tumor type to receive zenocutuzumab at a dose of 750 mg intravenously every 2 weeks. The primary end point was overall response (complete or partial response) according to investigator assessment. Secondary end points included duration of response, progression-free survival, and safety.
Citation impact
103
total citations
- FWCI
- 80.88
- Percentile
- 100%
- References
- 27
Citations per year
Authors
32- AMAlison M. SchramCorresponding
Memorial Sloan Kettering Cancer Center, Cornell University
- KGKōichi Goto
National Cancer Center Hospital East
- DKDong-Wan Kim
Seoul National University Hospital
- TMTeresa Macarulla
Hebron University, Vall d'Hebron Institute of Oncology
- AHAntoine Hollebecque
Institut Gustave Roussy
Topics & keywords
Topics
Keywords
- Medicine
- Cancer
- Fusion
- Oncology
- Internal medicine
- Mathematics
- Philosophy
UN Sustainable Development Goals
- Zero hunger
No related works found for this paper.